IDEC Pharmaceuticals Announces Estimated Net Income of $0.22 Per Share in Third Quarter of 2002

(BUSINESS WIRE) — IDEC Pharmaceuticals Corporation (Nasdaq: IDPH) today announced a preliminary net income estimate of approximately $0.22 per share on a diluted basis for the third quarter of 2002.

This level of net income for the three months ended September 30, 2002 was achieved through the combination of U.S. net sales of Rituxan(R)(rituximab) totaling $269.5 million, which IDEC copromotes in the U.S. with Genentech, Inc., and U.S. net sales of Zevalin(TM) (ibritumomab tiuxetan) totaling $5.0 million, which IDEC markets alone in the U.S.

U.S. net sales of Rituxan as recorded by Genentech for the third quarter of 2002 increased $64.5 million to $269.5 million, compared to $205 million from the third quarter of 2001, representing a 31 percent increase from the same quarter last year.

The $293.8 million of net sales of Rituxan reported by Genentech in the third quarter included $24.3 million of ex-U.S. sales to its partners F. Hoffmann-La Roche Ltd. and Zenyaku Kogyo Co. Ltd. of Japan. IDEC’s royalty revenue on sales of Rituximab outside the U.S. was $11.8 million in the third quarter, which is based on Roche’s and Zenyaku’s end-user sales and is booked with a one-quarter lag.

IDEC’s actual results for the third quarter are expected to be released on October 16, 2002, after the close of market. Following the release, IDEC will host a live webcast of a discussion by IDEC management between 1:30 p.m. and 2:30 p.m. PST. The webcast will be accessible through IDEC’s website at and will be archived for 10 business days.

Rituxan was discovered by IDEC and is copromoted in the United States by IDEC and Genentech. Rituxan is jointly developed by IDEC, Genentech Inc., F. Hoffmann-La Roche Ltd. of Switzerland and Zenyaku Kogyo Co. Ltd. of Japan. Roche has marketing rights to Rituximab outside of the United States, and copromotes Rituxan in Japan in collaboration with Zenyaku Kogyo. Zevalin was discovered and is promoted in the U.S. by IDEC. Schering AG retains marketing and distribution rights to Zevalin outside the U.S.

IDEC Pharmaceuticals Corporation is a leader in the discovery, development, and commercialization of targeted immunotherapies for the treatment of cancer and autoimmune diseases. IDEC discovered and developed the first commercially available radioimmunotherapy product (Zevalin) approved in the United States and, with co-promotion partner Genentech, Inc., the first monoclonal antibody product (Rituxan) approved in the United States, both for the treatment of cancer. IDEC is a San Diego based, integrated biopharmaceutical company with multiple products in clinical stage development and strategic alliances in a variety of research platforms. For a menu of IDEC’s current news releases and quarterly reports or to retrieve a specific release, call (888) 329-2309. On the Internet check the News Center at IDEC’s website:

The statements made in this press release contain certain forward-looking statements that involve a number of risks and uncertainties. Actual events or results may differ from IDEC’s expectations. For example, the timing, success and cost of preclinical research and clinical studies, the timing, acceptability and review periods for regulatory filings, the timing of and ability to obtain regulatory approval of products, the timing of product launches, the achievement of future product sales, the level of manufacturing performance and the risk factors listed from time to time in IDEC’s SEC filings including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2001 and Form 10-Q for the second quarter ended June 30, 2002, which may affect the actual results achieved by IDEC. These forward-looking statements represent the company’s judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

IDEC Pharmaceuticals and Rituxan are registered U.S. trademarks of the company. Zevalin is a trademark of the company. The company’s headquarters is located at 3030 Callan Road, San Diego, CA 92121.CONTACT: IDEC Pharmaceuticals Corporation Vince Reardon, Director, Corporate Communications 858/431-8656

News provided by COMTEX. User agreement applies